Effects of ß-Lactam Antibiotics and Fluoroquinolones on Human Gut Microbiota in Relation to Clostridium difficile Associated Diarrhea by Knecht, H. et al.
Effects of b-Lactam Antibiotics and Fluoroquinolones on
Human Gut Microbiota in Relation to Clostridium difficile
Associated Diarrhea
Henrik Knecht1., Sven C. Neulinger2., Femke Anouska Heinsen1, Carolin Knecht3, Anke Schilhabel2,
Ruth A. Schmitz2, Alexandra Zimmermann1, Vitor Martins dos Santos4,5, Manuel Ferrer6,
Philip C. Rosenstiel1, Stefan Schreiber1,7, Anette K. Friedrichs1,7", Stephan J. Ott1,7*"
1 Institute of Clinical Molecular Biology (IKMB), Christian-Albrechts-University (CAU), Kiel, Germany, 2 Institute for General Microbiology (IFAM), Christian-Albrechts-
University (CAU), Kiel, Germany, 3 Institute of Medical Informatics and Statistics (IMIS), Christian-Albrechts-University (CAU), Kiel, Germany, 4 Systems and Synthetic
Biology, Wageningen University, Wageningen, The Netherlands, 5 LifeGlimmer GmbH, Berlin, Germany, 6 Laboratory of Enzyme Discovery, CSIC - Institute of Catalysis,
Madrid, Spain, 7Department of Internal Medicine I, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany
Abstract
Clostridium difficile infections are an emerging health problem in the modern hospital environment. Severe alterations of the
gut microbiome with loss of resistance to colonization against C. difficile are thought to be the major trigger, but there is no
clear concept of how C. difficile infection evolves and which microbiological factors are involved. We sequenced 16S rRNA
amplicons generated from DNA and RNA/cDNA of fecal samples from three groups of individuals by FLX technology: (i)
healthy controls (no antibiotic therapy); (ii) individuals receiving antibiotic therapy (Ampicillin/Sulbactam, cephalosporins,
and fluoroquinolones with subsequent development of C. difficile infection or (iii) individuals receiving antibiotic therapy
without C. difficile infection. We compared the effects of the three different antibiotic classes on the intestinal microbiome
and the effects of alterations of the gut microbiome on C. difficile infection at the DNA (total microbiota) and rRNA
(potentially active) levels. A comparison of antibiotic classes showed significant differences at DNA level, but not at RNA
level. Among individuals that developed or did not develop a C. difficile infection under antibiotics we found no significant
differences. We identified single species that were up- or down regulated in individuals receiving antibiotics who developed
the infection compared to non-infected individuals. We found no significant differences in the global composition of the
transcriptionally active gut microbiome associated with C. difficile infections. We suggest that up- and down regulation of
specific bacterial species may be involved in colonization resistance against C. difficile providing a potential therapeutic
approach through specific manipulation of the intestinal microbiome.
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Introduction
Clostridium difficile-associated diarrhea (CDAD) is caused by C.
difficile toxins A and B and represents a serious burden for the
clinical environment and the health care system [1]. Although the
natural intestinal microbiota of healthy individuals can prevent
colonization by C. difficile [2,3], the incidence of C. difficile
infections has increased in the last decade [4]. Although
approximately 5% of the adult population is colonized by C.
difficile without showing any symptoms of diarrhea, the coloniza-
tion rate increases up to 20% in hospitalized individuals [5]. Other
factors such as advanced age, parenteral nutrition, renal insuffi-
ciency, previous hospitalizations, treatment with proton pump
inhibitors and previous antibiotic (AB) treatment increase the risk
of developing CDAD [6–8]. Several studies have shown an
association between AB treatments such as Ampicillin, cephalo-
sporins and fluoroquinolones and an increased risk of developing
CDAD [9,10]. AB treatment can lead to AB-induced dysbiosis of
the host-associated microbiome, with the potential absence of
important gut microbial commensal species and an indirect break
of mutualistic interactions [11,12]. This dysbiosis may result in the
unlimited expansion of C. difficile [13,14]. Only a few studies have
investigated the effect of AB on the dynamic changes of the
intestinal microbiome in relation to the development of CDAD in
humans. In additions to an increase of C. difficile, shifts within
Bacteroidetes, C. coccoides, Eubacterium rectale, Ruminococcus gnavus and
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C. nexile have been shown [15]. A marked decrease in the
microbial alpha diversity (the variety of organisms inhabiting a
defined habitat) is likely responsible for facilitating intestinal
colonization with C. difficile as has been observed by temperature
gradient gel electrophoresis (TGGE) and bacterial clone libraries
[14–16]. Manges et al. illustrated that low levels of Bacteroidetes
are significantly associated with CDAD [14] and other data
suggest that the absence of Bacteroidetes results in chronically
relapsing C. difficile diarrhea [17]. A study investigating C. difficile-
colonized infants revealed that low Firmicutes and Bacteroidetes
ratios and an increase in facultative anaerobes facilitate coloniza-
tion with C. difficile [18]. No previous studies have highlighted the
specific role of the species present in the gut microbiota (indicated
by the amounts of the 16S rRNA genes generated from DNA) and
particularly the metabolically active species (indicated by the
amounts of the 16S rRNA amplicons generated from cDNA) in
individuals with CDAD due to antibiotic therapy [19].
We hypothesize that the gut microbial composition of individ-
uals who develop CDAD is different from that of CDAD-negative
individuals, in terms of the total and the active microbiota as
determined by alpha and beta diversity measures. We further
postulate that the alteration of the gut microbial composition is
similar for different ABs (fluoroquinolones, cephalosporins and
Ampicillin/Sulbactam).
Results
We compared the total microbiota and the microbiota with
protein synthesis potential (potentially active) [19] of individuals
developing CDAD to those not developing CDAD during the
course of AB treatment with cephalosporins or Ampicillin/
Sulbactam (n = 5 each). This investigation was conducted by
analysis of the V1–V2 variable regions of the bacterial 16S rRNA
gene amplified from DNA or cDNA generated from RNA. We
also investigated alterations of the gut microbiota composition
induced by AB treatment with different AB classes, including
fluoroquinolones, cephalosporins and Ampicillin/Sulbactam
(n= 5 each). Control cases (n = 18) who did not receive antibiotic
therapy were also included in the study.
Pyrosequencing yielded 524,582 sequences across all samples
after preprocessing and a quality check. Sequences have been
deposited in MG-RAST (http://metagenomics.anl.gov) under
accession numbers 4546490.3 to 4546560.3. Random subsam-
pling produced 96,387 sequences (1,083 reads for each sample) for
further analysis. The sequences were binned at the 97% similarity
level into a total of 4,991 operational taxonomic units (OTUs),
with 2,763 and 3,175 OTUs at the DNA and RNA levels,
respectively, with an avg. length of 355 bp in both cases.
Alpha diversity
As illustrated in Figure 1 and 2, significant differences in
bacterial alpha diversity at the DNA (P C. difficile DNA= 0.05) but not
at the RNA level (P C. difficile RNA=0.86) were found between
individuals with CDAD and the individuals without CDAD during
AB therapy. Differences between the effects of Ampicillin/
Sulbactam and cephalosporin treatments were not significant at
either level (P AB DNA= 0.90, P AB RNA= 0.20). Consequentially,
these antibiotics were treated as one group, named the ß-lactams
(Ampicillin/Sulbactam/cephalosporins) in comparison to the
fluoroquinolones and controls. Pair-wise differences regarding
the bacterial alpha diversity of the healthy individuals and
individuals treated with the ß-lactam antibiotics or fluoroquino-
lones were not statistically significant at the DNA level. At the
RNA level the difference between healthy controls and individuals
Figure 1. Distribution of Shannon number equivalents at DNA level concerning CDAD positive and CDAD negative individuals.
doi:10.1371/journal.pone.0089417.g001
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treated with ß-lactam antibiotics reached statistical significance
(Figure S1) (P Contr-ß-lactam RNA= 0.01).
Beta diversity
Redundancy analyses (RDA) with subsequent pair-wise com-
parisons were used to assess the differences in total and potentially
active OTUs of the gut microbial community in the individuals
with and without CDAD development during AB treatment. No
significant difference was found in total and potentially active gut
microbiota of individuals with CDAD compared to individuals
without CDAD.
Individuals treated with Ampicillin/Sulbactam or cephalospo-
rins showed no significant differences in total and potentially active
gut microbiota. These groups were further treated as one group
(cephalosporins/Ampicillin/Sulbactam (ß-lactam)). Graphical rep-
resentations of the RDA models are shown in Figure 3 (DNA) and
4 (RNA). The gut microbiota of individuals treated with ß-lactam
were significantly different from those treated with fluoroquino-
lones at the DNA level (PDNA,0.01), but not at the RNA level
(PRNA= 0.26). Healthy controls harbored gut microbiota signifi-
cantly different compared to those of individuals treated with
either ß-lactam antibiotics or fluoroquinolones at both levels (Pß-
Lactam DNA,0.01, Pfluoroquinolones DNA,0.01, Pß-Lactam RNA,0.01,
Pfluoroquinolones RNA,0.01).
Bacterial distribution in fecal samples (OTU-independent)
As shown in Figures S2 and S3, fluctuations among the relative
amounts of bacterial phyla and families were observed at the DNA
and RNA levels. Firmicutes were the dominant phylum in all
control and AB samples.
Compared to controls, treatment with ß-lactam antibiotics
resulted in a decrease in Firmicutes and increase of Bacteroidetes
at the DNA and RNA levels. This decrease did not occur with
fluoroquinolone treatment. The relative amount of Proteobacteria
increased at DNA level (mean increase from 0,65%DNA-controls to
15%DNA-ß-lactam, 1,85%DNA-fluoroquinolones) and RNA level (mean
increase from 12,48%RNA-controls to 22,5%RNA-ß-lactam,
17,24%RNA-fluoroquinolones) due to treatment with ß-lactam antibi-
otics and fluoroquinolones in all individuals. At the bacterial
family level AB treatments resulted in an increase of Enterobac-
teriaceae (mean increase from 0,38%DNA-controls to 15%DNA-ß-
lactam, 1,7%DNA-fluoroquinolones) at DNA but not at RNA level.
Furthermore, a marked decrease of Lachnospiraceae, compared to
controls, at RNA level (mean decrease from 23%RNA-controls to
6,6%RNA-ß-lactam, 15%RNA-fluoroquinolones) was observed. Thereby,
reduction of Lachnospiraceae in individuals with CDAD (mean
decrease from 23%RNA-controls to 4,4%RNA-ß-lactam and 17%DNA-
controls to 4%DNA-ß-lactam) differed from individuals without CDAD
(mean decrease from 23%RNA-controls to 9%RNA-ß-lactam and
17%DNA-controls to 11%DNA-ß-lactam).
Indicator taxa
Indicator OTUs (in analogy to indicator taxa) are OTUs
predominant in a certain sample type while only irregularly found
in a comparison sample type. Because no significant difference in
gut microbial composition was observed among individuals treated
with different ABs at the RNA level (fluoroquinolones compared
to ß-lactam antibiotics), an indicator analysis was performed by
comparing all AB samples treated as one group to the healthy
controls at the RNA level. Indicator OTUs listed in Tables S1a–c
were responsible for differences between controls and individuals
treated with ß-lactam antibiotics and fluoroquinolones at DNA
level (Table S1a) and between controls and ABs at the RNA level
(Table S1b). Eighteen and 20 indicator OTUs were identified at
Figure 2. Distribution of Shannon number equivalents at RNA level concerning CDAD positive and CDAD negative individuals.
doi:10.1371/journal.pone.0089417.g002
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the DNA and RNA levels, respectively. Eight OTUs at RNA level
were indicators for healthy controls and showed homology to
Faecalibacterium prausnitzii, Coprococcus, Eubacterium, Lachnospiraceae
and Clostridium. Twelve OTUs were indicators for AB treatment,
affiliated with Blautia, Streptococcus parasanguinis, Clostridium ramnosum,
Enterococcus lacti, Halomonas, Propionibacterium acnes and Staphylococcus
epidermidis. At DNA level six OTUs indicating healthy controls
showed homology to Faecalibacterium prausnitzii, Coprococcus and
Eubacterium. Ten OTUs indicating fluoroquinolone treatment were
associated with Blautia, Subdoligranulum, Adlercreutzia, Clostridium and
Ruminococcus. Two OTUs (Enterobacter, and Enterococcus lacti)
indicated treatment with ß-lactam antibiotics.
No overall effect on the gut microbial composition was found in
case CDAD. Rather an effect was found on single OTUs, as few
microbial indicators could be identified as specific for CDAD
during AB treatment. Table S1c shows the indicator OTUs found
in individuals with and without CDAD at RNA and DNA levels;
briefly, four indicator OTUs associated to individuals with CDAD
(Streptococcus, Enhydrobacter and Granulicatella at RNA, and, as
expected, Clostridium difficile at the DNA level) and two in non-
CDAD individuals (Adlercreutzia and Collinsella at DNA level).
Discussion
C. difficile infections can be provoked by intestinal detrimental
events caused by AB-induced microbial imbalances and a loss of
colonization resistance. As bacterial protein synthesis potential
may indicate an important pathophysiological role, we examined
additionally to DNA the amounts of 16S rRNA amplicons
generated from cDNA in individuals receiving AB treatment.
Although a few studies have investigated these imbalances based
on AB treatment in the context of CDAD development in humans,
we present the first study based on high-throughput sequencing
technology that investigates the development of CDAD depending
on the gut microbial profiles associated with specific AB therapy.
As it was not possible to obtain larger sample sizes for each group
we expected to recognize only large effects between the compared
groups.
Decreased alpha diversity in CDAD development at the
DNA, but not at the RNA level
Alpha diversity expressed as effective OTU richness 1D (a.k.a.
Shannon numbers equivalent) was used to assess differences in
cumulative OTU abundance. 1D was consistently and significantly
higher (by factor 2) in individuals without CDAD than in
individuals with CDAD at the DNA level but not at the RNA
level. Higher 1D is associated with higher species richness and/or
evenness. Our results reveal that lower species richness at the
DNA level might be indicative of colonization with C. difficile.
These results at the DNA level are in agreement with the results of
Chang et al., who used bacterial clone libraries and observed that
an overall collapse of bacterial alpha diversity (Shannon index) is
responsible for C. difficile colonization [15]. Alpha diversity was not
significantly different at the RNA level, indicating a rather stable
potentially active microbiota. As the potentially active gut
microbiota is more important to the host, these results may be
more relevant. Results at RNA level contradict those at DNA level
Figure 3. Graphical representation (distance plots) of the redundancy analysis (RDA) model of Hellinger-transformed OTU
abundances. The model illustrate the relationship of gut microbes of healthy controls, individuals treated with ß-lactam antibiotic (Cephalosporins/
Ampicillin/Sulbactam) and individuals treated with fluoroquinolones at DNA level.
doi:10.1371/journal.pone.0089417.g003
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and support the assumption that the development of CDAD is not
related to a collapse in alpha diversity of the gut microbiota,
although AB therapy has decreased microbial a-diversity. It is
possible that a reduction in the amounts of specific potentially
active OTUs that may be involved in colonization resistance
against C. difficile correlates with a loss of their functional role in
the gut (i.e. the production of metabolites and antimicrobial
substances), which could predispose individuals to C. difficile
colonization.
Development of CDAD is independent of gut microbial
composition
The AB therapy used in this study affected the human gut
microbiota and led to compositional shifts. Gut microbial
composition showed no connection to CDAD development during
AB treatment with ß-lactam antibiotics at DNA or RNA level.
Because active gut bacterial diversity did not significantly change
with CDAD, the loss of colonization resistance against C. difficile
does not appear to be related to an overall collapse or overall
reduction of the composition of the human gut microbiota during
AB treatment. This trend was also shown by Reeves et al. in a
murine model [20], which suggested that specific changes of single
gut microbial members in the course of AB treatment may affect
the susceptibility of the host to C. difficile. This finding is consistent
with the clinical results of Blondeau et al. showing that the risk of
CDAD development differs with different ABs based on their
antimicrobial spectrum [21].
This study showed for the first time that development of CDAD
is not dependent on the specific composition of the potentially
active gut microbiota. The microbiota with protein synthesis
potential are more essential for the host than the inactive
microbiota because of factors such as metabolic turnover. Because
no specific active gut microbial composition is associated with
CDAD, the loss of colonization resistance against C. difficile is more
likely to depend on the amounts of specific gut microbial members
and their functional capacities rather than on the overall
compositional level. In cases of CDAD a loss of the functional
capacity of single species, possibly involving the production of
metabolites such as short chain fatty acids (SCFA) or antimicrobial
compounds, could allow the growth of C. difficile. Several
investigators have reported that low concentrations of SCFA in
the gut are associated with the presence of C. difficile [22,23].
Reeves et al. showed that high levels of Lachnospiraceae
contributed to colonization resistance against C. difficile or other
pathogens in mice [20]. Members of Lachnospiraceae have the
ability of ferment complex carbohydrates to SCFA and assist
maintaining intestinal homeostasis [24]. In our study the gut
microbiota of individuals with CDAD compared to CDAD
negative individuals showed lower amounts of Lachnospiraceae
as a result of AB treatment. Members of Lachnospiraceae were
further identified as an indicator OTU at RNA level belonging to
a healthy host. High or low levels of specific gut members such as
Lachnospiraceae in relation to their functional role could play a
central role in colonization resistance against C. difficile in humans.
A study involving collection of fecal samples of individuals before
Figure 4. Graphical representation (distance plots) of the redundancy analysis (RDA) model of Hellinger-transformed OTU
abundances. The model illustrate the relationship of gut microbes of healthy controls, individuals treated with ß-lactam antibiotic (Cephalosporins/
Ampicillin/Sulbactam) and individuals treated with fluoroquinolones at RNA level.
doi:10.1371/journal.pone.0089417.g004
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and during CDAD development in the course of AB treatment
could clarify the role of Lachnospiraceae and other specific gut
members in humans with regard to colonization resistance against
C. difficile.
Different AB classes reduce the same beneficial bacteria
and lead to an increase in opportunistic pathogens
We demonstrated that treatment with antibiotics such as
Ampicillin/Sulbactam and cephalosporins (both ß-lactam antibi-
otic) affected the total gut microbiota in a similar manner.
Treatment with fluoroquinolones affected the total gut microbiota
differently from b-lactam treatment. The effects of Ampicillin/
Sulbactam, cephalosporins and fluoroquinolones on the potential-
ly active gut microbiota were indistinguishable. This finding led to
the development of identical indicator OTUs at the RNA level for
the different AB classes. Indicator OTUs associated with
Faecalibacterium prausnitzii have been reported to be decreased due
to AB treatment [25]. A decrease in Faecalibacterium prausnitzii as a
result of AB treatment is important because this bacterium exhibits
anti-inflammatory capacity and a reduction in the amount of this
bacterium was shown to be associated with inflammatory diseases
such as Crohn’s disease (CD) or ulcerative colitis (UC) [2–27]. A
reduction in potentially active Coprococcus was induced by both AB
classes. This bacterium has been reported to be gut protective and
beneficial for human health [28–30]. There was an increase in
potentially active bacteria, including Streptococcus parasanguinis,
Clostridium rhamosum, Enterococcus lacti, Eggerthella lenta, Halomonas,
Ralstonia, and Propionibacterium acnes during AB treatment. The
presence of Streptococcus parasanguinis was shown in previous studies
to be associated with healthy oral microflora, and Eggerthella lenta
has been reported to be a cause of UC [31,32]. Propionibacterium
acnes is a known opportunistic pathogen that normally does not
harm its host. Low host resistance and high amounts of P. acnes
have been shown to be involved in prostate inflammation,
sarcoidosis and SAPHO (synovitis, acne, pustulosis, hyperostosis,
osteitis). The increase of these potentially active opportunistic
pathogens induced by AB medication may be important,
especially in association with decreased host resistance. The
observed higher amounts during AB therapy may be caused by AB
resistance mechanisms, as it has been reported for P. acnes and E.
lenta [33–35].
The effects of the ABs used in this study were similar at the
RNA level. Some ABs target cell wall synthesis (cephalosporins
and Ampicillin/Sulbactam), while others interfere with essential
bacterial enzymes (fluoroquinolones) [36,37]. This finding suggests
that the most important gut microbiota members with protein
synthesis potential are affected in similar ways independently of
the AB class. The majority of previous studies investigated the gut
microbiota during AB treatment at the level of total species (DNA).
These studies observed different shifts for different ABs [38–41].
Our results support the previous findings at the DNA level but not
at the RNA level. Similar effects of different ABs on the gut
microbiota at the RNA level could explain why various ABs are
associated with identical intestinal diseases such as AB-associated
diarrhea.
Conclusion
Employing high-throughput sequencing we showed that differ-
ent AB classes (Ampicillin/Sulbactam, cephalosporins and fluoro-
quinolones) affect the gut microbiota similarly at the RNA level
but differently at the DNA level. This finding explains why several
different AB classes are associated with similar intestinal problems.
CDAD development during AB therapy is not associated with a
specific gut microbial composition at the RNA or DNA level. AB
treatment affects the microbial composition and decreases the
bacterial a-diversity, but no overall diversity collapse caused by AB
treatment is responsible for the weak colonization resistance
against C. difficile. CDAD development is a multifactorial pattern
involving the interplay of gut microbial shifts and reduction of
specific gut members and diversity caused by AB treatment which
can lead to a lack of their functional integrity in colonization
resistance against C. difficile. Future studies should investigate the
development of CDAD and mechanisms of colonization resistance
based on functional methods such as metatranscriptomics or
metabolomics. Identification of single gut members contributing to
colonization resistance may be helpful in determining the process
of CDAD development in humans and may allow development of
specific probiotics against CDAD. Furthermore, as we could not
check for the type of C.difficile strains in infected patients, it would
be interesting in future studies to characterize the type of C.difficile
strains from gut samples of CDAD-positive individuals. This has
the potential to correlate C.difficile strain types with specific
changes of the gut microbiota as well as severity of clinical
symptoms.
Materials and Methods
Study design
Study volunteers provided fecal samples and were divided into
three different groups. Feces, collected from eighteen healthy
individuals, were used as controls in this study (named ‘‘Con-
trols’’). Furthermore, fecal samples were obtained from hospital-
ized individuals five days after starting a therapy with one of the
following antibiotic classes classified as fluoroquinolones (n = 5),
cephalosporins) (n = 5) or Ampicillin/Sulbactam (penicillins)
(n = 5) (named ‘‘AB-controls’’) in the Department for Internal
Medicine at the University Hospital Schleswig-Holstein, Campus
Kiel (UK-SH). Only samples obtained from individuals who did
not develop CDAD during and up to 3 months after the antibiotic
therapy were included in the group of AB controls. The third
group (named ‘‘C. difficile’’) consisted of fecal samples collected
from hospitalized individuals immediately after developing CDAD
during therapy with cephalosporins or Ampicillin/Sulbactam
(each with n= 5) (overview of study participants in Table S2).
Further criteria for participation in the study were: age 65 years or
older; no antibiotic, antimycotic or probiotic therapy in the
previous 6 months; no history of hospitalization or diarrhea in the
previous 6 months. All study participants gave general written
informed consent prior to admission to hospital including
molecular analysis of blood, biopsy and stool samples for scientific
reasons. An additional ethical vote for intestinal microbiota
analysis from stool samples was not deemed necessary by the
local ethical board of the Medical Faculty of the Christian-
Albrechts-University (CAU) in Kiel. Fecal samples were stored at
280uC until further use.
Tracking of Clostridium difficile in fecal samples
Because the production of toxin A and B by C. difficile strains is
associated with CDAD, all fecal samples were screened for
presence of these toxins as well as for glutamate dehydrogenase antigen
with an enzyme-linked immunosorbent assay (ELISA) at the
Institute of Infectious Diseases (UKSH, Campus Kiel). C. difficile
positivity of stool samples was verified by detection of the specific
C. difficile toxin A and B, with a membrane immunoassay
(TECHLAB; CLOSTRIDIUM DIFFICILE QUIK CHEK
COMPLETE KIT, Alere GmbH, Ko¨ln, Germany).
Antibiotics and C. diff. Associated Diarrhea
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Total DNA and RNA extraction
Total DNA extraction was performed with incubation of fecal
samples in 200 ml TL-buffer and 25 ml proteinase-K for two hours
at 56uC, before using the FastDNASPIN KIT FOR SOIL
(Qiagen, Hilden, Germany) as previously described [42]. Total
RNA from feces was isolated using the PowerMicrobiome RNA
Isolation Kit (MO BIO Laboratories Inc, Carlsbad, CA) following
the manufacturer’s protocol. Extracted RNA was reverse tran-
scribed into cDNA with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, USA)
according to the manufacturer’s instructions.
PCR amplification of variable region V1 to V2
The variable regions V1 and V2 of the 16S rRNA were
amplified. Samples preparation and high throughput sequencing
were performed according to previous studies [43].
Data cleansing and statistics
Data were preprocessed using MOTHUR version 1.27 [44] as
described before [43]. Data analysis and multivariate statistical
approaches were done in R v3.0.0 (http://www.R-project.org/).
Analyses were separately performed with DNA-and RNA-level
data. P-values in multiple testing scenarios were subjected to
Benjamini-Hochberg correction (‘‘q-values’’) [45]. Beta diversity
analysis was conducted via redundancy analysis (RDA) [46] as
implemented in the R package vegan v2.0-7 [47]. Count data of
operational taxonomic units (OTU; defined by 97% sequence
similarity) were Hellinger-transformed in order to produce valid
results in RDA [48]. Alpha diversity was described by effective
OTU richness 1D (known as the Shannon numbers equivalent)
[49,50], taking both the numbers and relative abundances of
OTUs into account. The 1D values were Box-Cox transformed to
meet homoscedasticity and normality of residuals in subsequent
analysis of variance (ANOVA).
In a first step, the effect of C. difficile associated diarrhea
development in connection with b-lactam AB classes cephalospo-
rins and Ampicillin/Sulbactam was assessed by a 262 factorial
ANOVA. A subsequent one-way ANOVA was conducted with
only AB as the independent factor, including also quinolones as
well as the control group. Data from C. difficile-positive individuals
were included in the second ANOVA if the C. difficile infection
effect was non-significant in the first one. With significance of the
second ANOVA, pairwise comparisons of factor levels were
conducted.
In beta diversity, OTUs most likely to be responsible for
differences between the group of AB treated individuals and
controls were determined. OTUs were pre-filtered by profile
likelihood selection [51] according to their vector lengths
calculated from RDA scores (scaling 1). Pre-filtered OTUs
significantly correlated with axes in the RDA model were
subjected to indicator analysis with the R package indicspecies
v1.6.7 [52].
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